Details for Patent: 5,164,369
✉ Email this page to a colleague
Title: | Pulmonary surfactant protein and related polypeptide |
Abstract: | The present invention relates to a human SP18 monomer protein-related polypeptide useful in forming a synthetic pulmonary surfactant. The present invention also relates to a method of treating neonatal respiratory distress syndrome comprising adminstering a therapeutically effective amount of synthetic pulmonary of the present invention. Further contemplated by the present invention is a composition containing human SP18 monomer and human SP18 dimer but no other pulmonary surfactant proteins. A recombinant DNA molecule capable of expressing, without post-translational proteolytic processing, mature human SP18 monomer, and methods of using the recombinant DNA molecule are also contemplated. |
Inventor(s): | Cochrane; Charles G. (La Jolla, CA), Revak; Susan D. (San Diego, CA) |
Assignee: | The Scripps Research Institute (La Jolla, CA) |
Filing Date: | Jan 04, 1989 |
Application Number: | 07/293,201 |
Claims: | 1. A polypeptide having an amino acid residue sequence selected from the group consisting of: DLLLLDLLLLDLLLLDLLLLD, RLLLLRLLLLRLLLLRLLLLR, RLLLLLLLLRLLLLLLLLRLL, RRLLLLLLLRRLLLLLLLRRL, RLLLLCLLLRLLLLLCLLLR, RLLLLLCLLLRLLLLCLLLRLL, and RLLLLCLLLRLLLLCLLLRLLLLCLLLR. 2. A synthetic pulmonary surfactant comprising a pharmaceutically acceptable phospholipid admixed with a polypeptide having an amino acid residue sequence selected from the group consisting of: DLLLLDLLLLDLLLLDLLLLD, RLLLLRLLLLRLLLLRLLLLR, RLLLLLLLLRLLLLLLLLRLL, RRLLLLLLLRRLLLLLLLRRL, RLLLLCLLLRLLLLLCLLLR, RLLLLLCLLLRLLLLCLLLRLL, and RLLLLCLLLRLLLLCLLLRLLLLCLLLR, said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone. 3. A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant, said surfactant comprising a pharmaceutically acceptable phospholipid admixed with an effective amount of a polypeptide having an amino acid residue sequence selected from the group consisting of: DLLLLDLLLLDLLLLDLLLLD, RLLLLRLLLLRLLLLRLLLLR, RLLLLLLLLRLLLLLLLLRLL, RRLLLLLLLRRLLLLLLLRRL, RLLLLCLLLRLLLLLCLLLR, RLLLLLCLLLRLLLLCLLLRLL, and RLLLLCLLLRLLLLCLLLRLLLLCLLLR, said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone. 4. A polypeptide having an amino acid residue sequence represented by the formula: RLLLLRLLLLRLLLLRLLLLR, said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone. 5. A synthetic pulmonary surfactant comprising a pharmaceutically acceptable phospholipid admixed with polypeptide wherein said polypeptide has an amino acid residue sequence represented by the formula: RLLLLRLLLLRLLLLRLLLLR, said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone. 6. A method of treating respiratory distress syndrome comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant, said surfactant comprising a pharmaceutically acceptable phospholipid admixed with an effective amount of polypeptide wherein said polypeptide has an amino acid residue sequence represented by the formula: RLLLLRLLLLRLLLLRLLLLR, said polypeptide, when admixed with a pharmaceutically acceptable phospholipid, forming a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone. |